ALK testing in non-small cell lung carcinoma: What now

Journal of Thoracic Oncology

Volumn 9, Issue 5, 2014, Pages 593-595

  Kerr, Keith M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTIBODY; ANTIBODY D5F3; BIOLOGICAL MARKER; CRIZOTINIB; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ALK GENE; CORRELATION ANALYSIS; DNA SEQUENCE; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; CHEMISTRY; LUNG TUMOR; NON SMALL CELL LUNG CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84899120690     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000171     Document Type: Editorial

References (23)

1. Lindeman NI Cagle PT Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859.
2. Kwak EL Bang YJ Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
3. Camidge DR Bang YJ Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.
4. Shaw AT Kim DW Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
5. Ou SH Bartlett CH Mino-Kenudson M Cui J Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17:1351-1375.
6. Tsao MS Hirsch FR Yatabe Y (Eds). IASLC Atlas of ALK Testing in Lung Cancer. Colorado USA: International Association for the Study of Lung Cancer 2013.
7. Soda M Choi YL Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
8. Mino-Kenudson M Chirieac LR Law K et al. A novel highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-1571.
9. Wynes MW Sholl LM Dietel M et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 2014;9:631-638.
10. Minca EC Portier BP Wang Z et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 2013;15:341-346.
11. Selinger CI Rogers TM Russell PA et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013;26:1545-1553.
12. Von Laffert M Warth A Penzel R et al. Anaplastic lymphoma kinase (ALK)-detection in non-small cell lung cancer: results of the first European IHC-based (D5F3-Optiview) panel test within 16 institutes. J Thorac Oncol 2013;8(Suppl 2):s484.
13. Blackhall F Peters S Kerr KM et al. Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: preliminary results from the European Thoracic Oncology Platform Lungscape project. Ann Oncol 2013;23(Suppl 9):ix73.
14. McLeer-Florin A Lantué joul S. Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer. J Thorac Dis 2012;4:240-241.
15. Karachaliou N Rosell R. Optimal detection of ALK rearranged lung adenocarcinomas. J Thorac Oncol 2013;8:255-256.
16. Kim H Xu X Yoo SB et al. Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases. Histopathology 2013;62:305-314.
17. Nitta H Tsuta K Yoshida A et al. New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new Brightfield dual ALK IHC-in situ hybridization assay. J Thorac Oncol 2013;8:1019-1031.
18. Prinsen CF Klaassen CH Thunnissen FB. Microarray as a model for quantitative visualization chemistry. Appl Immunohistochem Mol Morphol 2003;11:168-173.
19. Peled N Palmer G Hirsch FR et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012;7:e14-e16.
20. Sun JM Choi YL Won JK et al. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 2012;7:e36-e38.
21. Ross JS Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol 2011;136:527-539.
22. Frampton GM Fichtenholtz A Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031.
23. Chihara D Suzuki R. More on crizotinib. N Engl J Med 2011;364:776- 777;author reply 778.